> UCL spinout Engitix raised £5 million ($6.4 million). The series A tees the startup up to double the size of its R&D team and step up its research into drugs targeting liver fibrosis and certain cancers. Statement
> OMass Therapeutics named Ali Jazayeri as its CSO. Jazayeri is the former chief technology officer at Heptares Therapeutics. Release
> LifeArc and C4X Discovery teamed up to develop small molecule drug candidates against a novel oncology and inflammation target. C4XD will apply its ligand-focused conformational analysis platform to the program. Statement
> ADC Therapeutics began dosing patients in a phase 1/2 trial of its CD22-targeting antibody-drug conjugate, ADCT-602. The trial is testing ADCT-602 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Release
> Sensorion finished dosing patients in a phase 2a trial of seliforant in people susceptible to motion sickness. The study is due to deliver data by the end of the year. Separately, Sensorion began negotiating with Pasteur Institute for the rights to hearing loss gene therapy programs. Statement I More
> Immune Regulation posted phase 1 data on its lead compound PIN201104. The results cleared the British biotech to move the immunomodulator into a phase 2a study next year. Release